南微医学
(688029)
| 流通市值：154.20亿 | | | 总市值：154.20亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,727,947,419.23 | 853,734,897.79 | 3,183,783,900.37 | 2,380,540,402.29 |
| 营业总成本 | 1,348,475,630.82 | 670,832,383.74 | 2,480,891,306 | 1,755,895,594.02 |
| 其他经营收益 | | | | |
| 营业利润 | 377,686,481.32 | 181,630,262.24 | 691,689,338.27 | 626,310,214.27 |
| 利润总额 | 377,824,389.21 | 182,004,326.77 | 691,153,946.26 | 626,627,247.01 |
| 净利润 | 308,468,034.18 | 148,722,793.11 | 582,557,650.02 | 530,090,341.12 |
| 每股收益 | | | | |
| 其他综合收益 | -71,631,554.82 | -41,562,531.58 | 50,506,340.71 | 29,811,229.06 |
| 综合收益总额 | 236,836,479.36 | 107,160,261.53 | 633,063,990.73 | 559,901,570.18 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,337,498,558.79 | 3,304,918,483.94 | 3,642,199,115.16 | 3,475,983,589.07 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,100,962,257.9 | 2,032,413,976.82 | 1,821,593,506.6 | 1,716,428,619.23 |
| 资产总计 | 5,438,460,816.69 | 5,337,332,460.76 | 5,463,792,621.76 | 5,192,412,208.3 |
| 流动负债: | | | | |
| 流动负债合计 | 936,038,827.77 | 773,754,431.71 | 1,003,875,018.34 | 863,789,230.26 |
| 非流动负债: | | | | |
| 非流动负债合计 | 103,109,403.44 | 111,026,962.87 | 117,744,833.93 | 84,849,502.08 |
| 负债合计 | 1,039,148,231.21 | 884,781,394.58 | 1,121,619,852.27 | 948,638,732.34 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,187,069,191.71 | 4,242,095,493.25 | 4,130,443,252.66 | 4,071,956,863.63 |
| 股东权益合计 | 4,399,312,585.48 | 4,452,551,066.18 | 4,342,172,769.49 | 4,243,773,475.96 |
| 负债和股东权益合计 | 5,438,460,816.69 | 5,337,332,460.76 | 5,463,792,621.76 | 5,192,412,208.3 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,716,385,930.12 | 861,399,794.71 | 3,422,947,030.98 | 2,566,433,223.22 |
| 经营活动现金流出小计 | 1,466,423,677.87 | 754,997,016.01 | 2,735,001,277.35 | 2,088,904,722.76 |
| 经营活动产生的现金流量净额 | 249,962,252.25 | 106,402,778.7 | 687,945,753.63 | 477,528,500.46 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,198,936,641.87 | 2,482,436,060.16 | 1,626,230,255.44 | 940,416,025.24 |
| 投资活动现金流出小计 | 5,400,547,482.62 | 2,863,735,699.49 | 2,551,240,606.25 | 1,042,558,227.7 |
| 投资活动产生的现金流量净额 | -201,610,840.75 | -381,299,639.33 | -925,010,350.81 | -102,142,202.46 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 205,027,781.8 | 5,027,781.8 | 198,000,002.8 | 198,000,002.8 |
| 筹资活动现金流出小计 | 387,438,803.91 | 194,851,199.22 | 401,828,217.96 | 387,997,687.53 |
| 筹资活动产生的现金流量净额 | -182,411,022.11 | -189,823,417.42 | -203,828,215.16 | -189,997,684.73 |
| 汇率变动对现金及现金等价物的影响 | -74,043,735.23 | -41,618,903.54 | 7,352,730.89 | 30,364,694.28 |
| 现金及现金等价物净增加额 | -208,103,345.84 | -506,339,181.59 | -433,540,081.45 | 215,753,307.55 |
| 期末现金及现金等价物余额 | 1,228,572,710.91 | 930,336,875.16 | 1,436,676,056.75 | 2,085,969,445.75 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -208,103,345.84 | - | -433,540,081.45 | - |
最新报告期：2026-08-30| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 东吴证券 | 朱国广 | 3.25 | 4.14 | 4.88 | 2026-08-30 |
| 中泰证券 | 祝嘉琦,谢木青 | 3.22 | 3.70 | 4.46 | 2026-08-28 |
| 中国银河 | 孟熙,程培 | 3.20 | 3.76 | 4.39 | 2026-08-28 |
| 国信证券 | 凌珑,彭思宇,陈曦炳 | 3.20 | 3.79 | 4.82 | 2026-08-28 |
| 华泰证券 | 代雯,孔垂岩,王殷杰 | 2.92 | 3.36 | 4.00 | 2026-08-27 |